You would not fault executives at Basilea Pharmaceutica for crossing their fingers in the hope their string of bad luck may be over. A European advisory committee is due to report soon on the clinical practices of the trials supporting the skin-infection treatment ceftobiprole (Zevtera) run by Johnson & Johnson, Basilea’s development and marketing partner.
A positive verdict on the antibiotic seems highly unlikely given the strength of the FDA's recent rejection of the drug (Basilea weakened by FDA rejection, January 4, 2010). While a negative opinion should only prompt a modest share price decline, the outcome could prove an important factor in the ongoing arbitration between the two companies and enhance the risk that J&J will try and back out of the collaboration. Should this occur a potential silver lining for Basilea could emerge in a decent pay-off from J&J.
This content is written, edited and published by EP Vantage and is distributed by EvaluatePharma Ltd. All queries regarding the content should be directed to: news@epvantage.com
EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.
Drawing on EvaluatePharma, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.